Research programme: cancer therapeutics - EndocyteAlternative Names: CB-3717; EC 0531; EC 0651; EC 1812; EC 1868; EC 1977; EC-1744; EC1788; GARFTase inhibitors - Endocyte; PNU-159682
Latest Information Update: 28 Apr 2016
At a glance
- Originator Endocyte
- Developer Endocyte; Purdue University
- Class CAR-T cell therapies; Cell therapies; Depsipeptides; Doxorubicins; Drug conjugates; Folic-acids; Oligopeptides; Small molecules; Taxanes
- Mechanism of Action Folate receptor 1 antagonists; Glutamate carboxypeptidase II inhibitors; Immunostimulants; Phosphoribosylglycinamide formyltransferase inhibitors; Tubulin polymerisation inhibitors; Type II DNA topoisomerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Haematological malignancies; Prostate cancer; Solid tumours
- Research Cancer